Jason Perelman
Urology · Sunrise, FLNPI 1588659205
Payments from drug & device makers
Across 249 payments — averaging $44.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$4K
- Myriad Genetic Laboratories, Inc.$936
- Johnson & Johnson$713
- Olympus America Inc.$678
- Pfizer$582
- Procept Biorobotics Corporation$579
- plus $4K from 32 others
What the payments were for
- Consulting fees$3,35730%
- Travel & lodging$2472%
- Food & beverage$7,47567%
- Education$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 18 | $3,793 |
| Myriad Genetic Laboratories, Inc. | 24 | $936 |
| Johnson & Johnson(2 entities) | 31 | $713 |
| Olympus America Inc. | 10 | $678 |
| Pfizer | 18 | $582 |
| Procept Biorobotics Corporation | 6 | $579 |
| Rochester Medical Corporation | 7 | $537 |
| Bayer | 13 | $290 |
| Antares Pharma, Inc. | 13 | $289 |
| Sumitomo Pharma America, Inc. | 8 | $256 |
| AbbVie | 10 | $251 |
| Tolmar Pharmaceuticals, Inc. | 7 | $235 |
| Myovant Sciences Inc. | 8 | $229 |
| Endo Pharmaceuticals Inc. | 11 | $210 |
| Ferring Pharmaceuticals Inc. | 9 | $165 |
| Novartis | 6 | $148 |
| Urogen Pharma, Inc. | 2 | $130 |
| Teleflex LLC | 3 | $107 |
| Blue Earth Diagnostics | 4 | $105 |
| Verity Pharmaceuticals Inc. | 4 | $97 |
| Urovant Sciences Inc | 4 | $93 |
| ABC Home Medical Supply, Inc. | 4 | $82 |
| Merck | 3 | $71 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $63 |
| Immunitybio, Inc. | 3 | $63 |
| Tolmar, Inc. | 3 | $61 |
| Boston Scientific | 3 | $61 |
| Dendreon Pharmaceuticals LLC | 2 | $59 |
| Progenics Pharmaceuticals, Inc. | 2 | $54 |
| Bluewind Medical | 1 | $47 |
| BD | 2 | $40 |
| Coloplast | 2 | $39 |
| AstraZeneca | 1 | $25 |
| Halozyme Inc | 1 | $24 |
| Mission Pharmacal Company | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $23 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$3,590
- AquaBeam Robotic System$470
- ORGOVYX$349
- Soltive$262
- Gyrus ACMI$146
- ELIGARD$112
- Dornier MedTech$111
How this compares
$11,187 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 54 | $731,461 |
| Lupron DepotLeuprolide Acetate | 52 | $301,848 |
| NubeqaDarolutamide | 15 | $191,399 |
| MyrbetriqMirabegron | 326 | $183,493 |
| GemtesaVibegron | 134 | $88,081 |
| EligardLeuprolide Acetate | 21 | $28,967 |
| XyostedTestosterone Enanthate | 12 | $7,502 |
| Tamsulosin Hcl | 522 | $6,912 |
| Tadalafil | 51 | $3,284 |
| Testosterone Cypionate | 63 | $3,204 |
| Testosterone | 30 | $2,544 |
| Potassium Citrate ErPotassium Citrate | 17 | $2,431 |
| Silodosin | 27 | $2,408 |
| Finasteride | 182 | $2,175 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $1,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $3,793 | $914,954380 claims |
| AbbVieLupron Depot | $251 | $301,84852 claims |
| BayerNubeqa | $290 | $191,39915 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $256 | $88,081134 claims |
| Tolmar Pharmaceuticals, Inc.Eligard | $235 | $28,96721 claims |
| Antares Pharma, Inc.Xyosted | $289 | $7,50212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.
Other urology in Sunrise
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
- Paul CrispenGainesville$1.1M
- Craig HermanPompano Beach$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.